US Stock MarketDetailed Quotes

ABOS Acumen Pharmaceuticals

Watchlist
  • 1.200
  • -0.050-4.00%
Close Mar 10 16:00 ET
  • 1.200
  • 0.0000.00%
Post 20:01 ET
72.10MMarket Cap-0.87P/E (TTM)

Acumen Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
101.17%32.27M
80.89%24.38M
35.32%17.77M
35.15%61.14M
29.74%18.49M
41.05%16.04M
29.46%13.48M
42.68%13.14M
130.99%45.24M
69.32%14.25M
Selling and administrative expenses
3.25%5.02M
11.58%4.85M
20.42%5.33M
46.16%18.82M
48.29%5.19M
58.72%4.86M
40.61%4.35M
37.29%4.42M
76.89%12.88M
27.72%3.5M
-General and administrative expense
3.25%5.02M
11.58%4.85M
20.42%5.33M
46.16%18.82M
48.29%5.19M
58.72%4.86M
40.61%4.35M
37.29%4.42M
76.89%12.88M
27.72%3.5M
Research and development costs
143.73%27.25M
113.87%19.53M
42.88%12.45M
30.77%42.32M
23.70%13.29M
34.54%11.18M
24.75%9.13M
45.58%8.71M
162.99%32.36M
89.42%10.75M
Operating profit
-101.17%-32.27M
-80.89%-24.38M
-35.32%-17.77M
-35.15%-61.14M
-29.74%-18.49M
-41.05%-16.04M
-29.46%-13.48M
-42.68%-13.14M
-130.99%-45.24M
-69.32%-14.25M
Net non-operating interest income expense
-20.71%2.48M
49.26%2.81M
64.03%3.01M
326.84%10.21M
142.10%3.37M
371.19%3.12M
624.62%1.88M
2,310.53%1.83M
2,747.62%2.39M
2,145.16%1.39M
Non-operating interest income
12.16%3.5M
102.55%3.82M
118.61%4.01M
351.13%10.79M
183.84%3.95M
371.19%3.12M
624.62%1.88M
2,310.53%1.83M
2,747.62%2.39M
2,145.16%1.39M
Non-operating interest expense
--1.03M
--1M
--1M
--581K
--581K
--0
--0
--0
--0
----
Other net income (expense)
154.76%23K
6,550.00%1.03M
-2,500.00%-104K
-13,018.18%-1.44M
-13,710.00%-1.38M
-2,000.00%-42K
-16K
-500.00%-4K
99.99%-11K
-350.00%-10K
Gain on sale of security
---10K
--1.1M
---50K
---1.36M
----
----
----
----
----
----
Other non- operating income (expenses)
178.57%33K
-325.00%-68K
-1,250.00%-54K
-654.55%-83K
-110.00%-21K
-2,000.00%-42K
---16K
-500.00%-4K
-121.57%-11K
-350.00%-10K
Income before tax
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-22.20%-52.37M
-28.22%-16.5M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
57.40%-42.86M
-54.10%-12.87M
Income tax
Net income
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-22.20%-52.37M
-28.22%-16.5M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
57.40%-42.86M
-54.10%-12.87M
Net income continuous Operations
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-22.20%-52.37M
-28.22%-16.5M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
57.40%-42.86M
-54.10%-12.87M
Minority interest income
Net income attributable to the parent company
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-22.20%-52.37M
-28.22%-16.5M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
57.40%-42.86M
-54.10%-12.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-22.20%-52.37M
-28.22%-16.5M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
57.40%-42.86M
-54.10%-12.87M
Basic earnings per share
-108.33%-0.5
-21.43%-0.34
10.71%-0.25
-1.89%-1.08
9.38%-0.29
7.69%-0.24
-12.00%-0.28
-21.74%-0.28
78.88%-1.06
-55.13%-0.32
Diluted earnings per share
-108.33%-0.5
-21.43%-0.34
10.71%-0.25
-1.89%-1.08
9.38%-0.29
7.69%-0.24
-12.00%-0.28
-21.74%-0.28
78.88%-1.06
-55.13%-0.32
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 101.17%32.27M80.89%24.38M35.32%17.77M35.15%61.14M29.74%18.49M41.05%16.04M29.46%13.48M42.68%13.14M130.99%45.24M69.32%14.25M
Selling and administrative expenses 3.25%5.02M11.58%4.85M20.42%5.33M46.16%18.82M48.29%5.19M58.72%4.86M40.61%4.35M37.29%4.42M76.89%12.88M27.72%3.5M
-General and administrative expense 3.25%5.02M11.58%4.85M20.42%5.33M46.16%18.82M48.29%5.19M58.72%4.86M40.61%4.35M37.29%4.42M76.89%12.88M27.72%3.5M
Research and development costs 143.73%27.25M113.87%19.53M42.88%12.45M30.77%42.32M23.70%13.29M34.54%11.18M24.75%9.13M45.58%8.71M162.99%32.36M89.42%10.75M
Operating profit -101.17%-32.27M-80.89%-24.38M-35.32%-17.77M-35.15%-61.14M-29.74%-18.49M-41.05%-16.04M-29.46%-13.48M-42.68%-13.14M-130.99%-45.24M-69.32%-14.25M
Net non-operating interest income expense -20.71%2.48M49.26%2.81M64.03%3.01M326.84%10.21M142.10%3.37M371.19%3.12M624.62%1.88M2,310.53%1.83M2,747.62%2.39M2,145.16%1.39M
Non-operating interest income 12.16%3.5M102.55%3.82M118.61%4.01M351.13%10.79M183.84%3.95M371.19%3.12M624.62%1.88M2,310.53%1.83M2,747.62%2.39M2,145.16%1.39M
Non-operating interest expense --1.03M--1M--1M--581K--581K--0--0--0--0----
Other net income (expense) 154.76%23K6,550.00%1.03M-2,500.00%-104K-13,018.18%-1.44M-13,710.00%-1.38M-2,000.00%-42K-16K-500.00%-4K99.99%-11K-350.00%-10K
Gain on sale of security ---10K--1.1M---50K---1.36M------------------------
Other non- operating income (expenses) 178.57%33K-325.00%-68K-1,250.00%-54K-654.55%-83K-110.00%-21K-2,000.00%-42K---16K-500.00%-4K-121.57%-11K-350.00%-10K
Income before tax -129.72%-29.77M-76.89%-20.54M-31.54%-14.87M-22.20%-52.37M-28.22%-16.5M-20.98%-12.96M-14.37%-11.61M-23.86%-11.31M57.40%-42.86M-54.10%-12.87M
Income tax
Net income -129.72%-29.77M-76.89%-20.54M-31.54%-14.87M-22.20%-52.37M-28.22%-16.5M-20.98%-12.96M-14.37%-11.61M-23.86%-11.31M57.40%-42.86M-54.10%-12.87M
Net income continuous Operations -129.72%-29.77M-76.89%-20.54M-31.54%-14.87M-22.20%-52.37M-28.22%-16.5M-20.98%-12.96M-14.37%-11.61M-23.86%-11.31M57.40%-42.86M-54.10%-12.87M
Minority interest income
Net income attributable to the parent company -129.72%-29.77M-76.89%-20.54M-31.54%-14.87M-22.20%-52.37M-28.22%-16.5M-20.98%-12.96M-14.37%-11.61M-23.86%-11.31M57.40%-42.86M-54.10%-12.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -129.72%-29.77M-76.89%-20.54M-31.54%-14.87M-22.20%-52.37M-28.22%-16.5M-20.98%-12.96M-14.37%-11.61M-23.86%-11.31M57.40%-42.86M-54.10%-12.87M
Basic earnings per share -108.33%-0.5-21.43%-0.3410.71%-0.25-1.89%-1.089.38%-0.297.69%-0.24-12.00%-0.28-21.74%-0.2878.88%-1.06-55.13%-0.32
Diluted earnings per share -108.33%-0.5-21.43%-0.3410.71%-0.25-1.89%-1.089.38%-0.297.69%-0.24-12.00%-0.28-21.74%-0.2878.88%-1.06-55.13%-0.32
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Trending Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Symbol Mini Chart % Chg
Lantheus
LNTH
+3.45%
Collegium Pharmaceutical
COLL
+2.59%
Constellation Brands
STZ
+1.73%
Halozyme Therapeutics
HALO
+0.75%
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
0.00%

Unlock the Full List